Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo  Expanded indication marks second disease for which Dupixent is approved in children this young, underscoring the commitment to bringing therapies to young patients with significant unmet needs  EoE is one of five FDA-approved i ...

TARRYTOWN, N.Y. and WASHINGTON, D.C., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Society for Science (the Society) today announced the top 40 finalists in this year's Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors. The competition, now in its 83rd year, has consistently identified young innovators who combine their STEM talent with dedication and leadership skills to drive society forward ...

Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced that the FDA has updated the label for Dupixent (dupilumab) for the indication of atopic dermatitis.Per the latest FDA update, efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement will be added to the existing label.The label update is based on data from the late-stage LIBERTY-AD-HAFT study, which evaluated the efficacy and safety of Dupi ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Regeneron CEO Leonard Schleifer elaborated on the biotech company's latest ventures with CNBC's Jim Cramer on Tuesday and emphasized the importance of genetic research across the industry."The big thing for everybody these days is AI, that's the next big thing. But I don't believe that," Schleifer said. "It's a good tool. But for our business, the really, most important tool, I think, is genetics, it's genes."Schleifer suggested that "associating genes with disease" is going to drive the pharmaceutical indu ...

Shares of Regeneron Pharmaceuticals, Inc. (REGN) declined 1.13% after the company reported disappointing fourth-quarter preliminary sales for lead drug, Eylea.Sales of Eylea (aflibercept) and Eylea HD (higher dose of Eylea) came in at $1.46 billion in the United States. The Zacks Consensus Estimate for the same was $1.45 billion.Eylea sales came in at $1.34 billion in the United States and Eylea HD sales came in at $123 million in the fourth quarter of 2023. This was the first full quarter for Eylea HD foll ...

Regeneron Pharmaceuticals Inc. - Key Takeaways from the 42nd Annual JPMorgan Healthcare Conference Call Company Overview - **Company**: Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) - **Date**: January 8, 2024 - **Participants**: Leonard Schleifer (CEO), George Yancopoulos (CSO), Marion McCourt (EVP, Commercial) Core Industry Insights 2023 Performance Highlights - 2023 was a successful year with significant progress in both core products and pipeline development [2][5] - Key products include EYLEA and DUPIXENT, with EYLEA HD launched in August 2023 [5][7] - DUPIXENT achieved approximately $8.4 billion in sales in the first nine months of 2023, reflecting a 34% growth [8][9] EYLEA HD Launch - EYLEA HD generated $123 million in its first quarter, indicating strong market acceptance despite some prescriber hesitancy due to lack of a permanent J-code [7][8] - Approximately two-thirds of lives are covered, and a permanent J-code is expected to enhance reimbursement confidence by April 2024 [8][36] DUPIXENT Developments - DUPIXENT has been approved for five indications and is expected to launch for COPD, targeting approximately 500,000 patients in the G7 [10][20] - The product has shown a remarkable safety profile and efficacy across various allergic diseases [9][21] Pipeline and Innovation Oncology Pipeline - Regeneron is focusing on immuno-oncology, with three validated classes of immunomodulatory agents [14][15] - The company aims to be a leading oncology player by the end of the decade, with significant advancements in bispecific antibodies [10][15] - Upcoming pivotal data expected from ongoing trials, particularly in melanoma and multiple myeloma [17][57] Genetic Medicines - Regeneron is advancing genetic medicine initiatives, including CRISPR and siRNA technologies, with several programs entering clinical trials [26][27] - The collaboration with Alnylam has achieved proof-of-concept for silencing genes in the liver and brain [26] Obesity and Muscle Preservation - Regeneron is developing antibodies to improve weight loss quality by preserving muscle mass during caloric restriction [24][25] - Early data shows promising results in preclinical models, with trials expected to initiate soon [25] Future Opportunities Severe Allergies - A novel combination approach using DUPIXENT and BCMA bispecific is being explored to potentially reverse severe allergies [21][22] - Clinical trials are planned to assess the safety and efficacy of this combination [52] COPD and Other Indications - The company is preparing for the launch of DUPIXENT for eosinophilic COPD, with strong enthusiasm from pulmonologists [44][46] - Itepekimab, an IL-33 antibody, is also in development for a distinct subset of COPD patients [20] Conclusion - Regeneron is positioned for continued growth with a robust pipeline and innovative approaches across various therapeutic areas, including oncology, genetic medicine, and immunology [12][32] - The company emphasizes its commitment to scientific innovation and improving patient outcomes while maintaining a focus on corporate responsibility [32]

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) 42nd Annual JPMorgan Healthcare Conference Call January 8, 2024 5:15 PM ET Company Participants Chris Schott - JPMorgan Leonard Schleifer - Board Co-Chair, President and Chief Executive Officer George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - Executive Vice President, Commercial Chris Schott Good afternoon, everybody. I'm Chris Schott from JPMorgan, and it's my pleasure to be introducing Regeneron today. Fro ...

SolStock/E+ via Getty Images Investment Overview Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), the Tarrytown, New York State-based Pharma company, have been rising sharply in recent months, from $725 in mid-August 2023, to >$910 at the time of writing - up >25%. Regeneron's share float is only just over 100m, and its market cap valuation currently hovers around the $100bn mark. Arguably, that is a generous valuation for a company that has generated top line revenues of $6.6bn, $8.5bn, $16.1bn, an ...

About this content About Stephen Gunnion Stephen Gunnion is a senior financial journalist and broadcaster at Proactive Investors. He has more than 25 years of experience in television, radio and print media, anchoring on a number of television channels including South Africa's Business Day TV, CNBC Africa and the South African Broadcasting Corporation, where he was the economics editor. He has also worked for Daily Maverick, Bloomberg, the Business Day newspaper and Investors' Chronicle. Read more About ...